With Amgen having recently reacquired the sales rights to three of its drugs, the company’s GM in Singapore and Malaysia, Raphael Ho, explains the rationale behind Amgen’s recent entry in Singapore and his experience in setting up the affiliate, while also expounding upon the unique value of Amgen products in addressing unmet medical needs.
As an introduction for our readers, could you please provide some insight into Amgen’s presence within Singapore?
Our business development plan is aligned with our recently established Next-Generation Biomanufacturing facility in Singapore, which will manufacture some of the products that we’ll be commercializing here
